$8.99
▲ +0.6% Today
as of Sep 4, 16:53 ET
Last 30 days
Recent Press Releases & News
Regenxbio’s Gene Therapy Faces Another FDA Setback in Hunter Syndrome
REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli
Regenxbio’s RGX-121 Setback Carries A Potential Cash Risk, Warns Clear Street
Overview
52-week range
$5.46
$16
33% of range
Avg surprise (last 3)
-39.8%
Avg reaction (last 2)
-15.9%
50% positive
Latest IV / EM
85%
EM ±13.3% · $9 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $0.43 | — | — | — | — | financials |
| Thu May 14, 2026 | Mar/2026 | $-1.72 | $-1.36 | -26.5% | -1,533% | -37.8% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-1.20 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-1.38 | $-1.13 | -22.1% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $0.12 | $0.41 | -70.7% | — | +6.0% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-1.17 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1.05 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-1.38 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-1.41 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-1.66 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-1.53 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $108M | $6M | — | $30M | $21M | $89M | — | $24M |
| Cost of revenue | — | — | — | — | — | — | — | $12M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $29M | $-83M | — | $-52M | $-63M | $12M | — | $-62M |
| Net income | $23M | $-90M | — | $-62M | $-71M | $6M | — | $-60M |
| EPS (diluted) | $0.43 | $-1.72 | — | $-1.20 | $-1.38 | $0.12 | — | $-1.17 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $36M | $15M | $34M | $59M | $80M | $130M | $58M | $57M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $236M | $187M | $281M | $332M | $374M | $313M | $278M | $313M |
| Total assets | $387M | $342M | $453M | $525M | $581M | $491M | $466M | $519M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $315M | $321M | $350M | $364M | $367M | $217M | $206M | $218M |
| Total equity | $72M | $21M | $103M | $161M | $214M | $274M | $260M | $301M |